Medy-Tox Inc.

KOSDAQ:A086900 Stock Report

Market Cap: ₩834.7b

Medy-Tox Valuation

Is A086900 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A086900 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A086900 (₩124000) is trading below our estimate of fair value (₩306439.3)

Significantly Below Fair Value: A086900 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A086900?

Key metric: As A086900 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A086900. This is calculated by dividing A086900's market cap by their current earnings.
What is A086900's PE Ratio?
PE Ratio77.8x
Earnings₩10.73b
Market Cap₩834.68b

Price to Earnings Ratio vs Peers

How does A086900's PE Ratio compare to its peers?

The above table shows the PE ratio for A086900 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.3x
A145020 Hugel
27.6x22.0%₩3.1t
A214450 PharmaResearch
29.7x27.9%₩2.6t
A096530 Seegene
36.8x35.2%₩1.1t
A182400 NKMAX
11xn/a₩172.7b
A086900 Medy-Tox
77.8x63.3%₩834.7b

Price-To-Earnings vs Peers: A086900 is expensive based on its Price-To-Earnings Ratio (77.8x) compared to the peer average (26.3x).

Price to Earnings Ratio vs Industry

How does A086900's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A086900 77.8xIndustry Avg. 30.3xNo. of Companies10PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A086900 is expensive based on its Price-To-Earnings Ratio (77.8x) compared to the Asian Biotechs industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is A086900's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A086900 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio77.8x
Fair PE Ratio40.7x

Price-To-Earnings vs Fair Ratio: A086900 is expensive based on its Price-To-Earnings Ratio (77.8x) compared to the estimated Fair Price-To-Earnings Ratio (40.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A086900 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩124,000.00
₩210,000.00
+69.4%
14.3%₩260,000.00₩170,000.00n/a6
Dec ’25₩131,400.00
₩210,000.00
+59.8%
14.3%₩260,000.00₩170,000.00n/a6
Nov ’25₩164,800.00
₩257,500.00
+56.3%
10.4%₩300,000.00₩230,000.00n/a4
Oct ’25₩192,400.00
₩257,500.00
+33.8%
10.4%₩300,000.00₩230,000.00n/a4
Sep ’25₩198,100.00
₩257,500.00
+30.0%
10.4%₩300,000.00₩230,000.00n/a4
Aug ’25₩173,000.00
₩276,000.00
+59.5%
31.4%₩390,000.00₩180,000.00n/a5
Jul ’25₩150,100.00
₩268,000.00
+78.5%
35.0%₩390,000.00₩170,000.00n/a5
Jun ’25₩130,600.00
₩296,000.00
+126.6%
33.5%₩390,000.00₩170,000.00n/a5
May ’25₩135,000.00
₩296,000.00
+119.3%
33.5%₩390,000.00₩170,000.00n/a5
Apr ’25₩147,000.00
₩296,000.00
+101.4%
33.5%₩390,000.00₩170,000.00n/a5
Mar ’25₩158,000.00
₩318,333.33
+101.5%
19.8%₩390,000.00₩220,000.00n/a6
Feb ’25₩190,400.00
₩328,333.33
+72.4%
22.6%₩430,000.00₩220,000.00n/a6
Jan ’25₩241,000.00
₩335,000.00
+39.0%
24.2%₩430,000.00₩220,000.00n/a6
Dec ’24₩222,500.00
₩335,000.00
+50.6%
24.2%₩430,000.00₩220,000.00₩131,400.006
Nov ’24₩205,500.00
₩350,000.00
+70.3%
23.1%₩430,000.00₩220,000.00₩164,800.005
Oct ’24₩252,500.00
₩345,000.00
+36.6%
26.0%₩430,000.00₩220,000.00₩192,400.004
Sep ’24₩251,000.00
₩332,500.00
+32.5%
24.0%₩430,000.00₩220,000.00₩198,100.004
Aug ’24₩216,000.00
₩330,000.00
+52.8%
22.2%₩410,000.00₩220,000.00₩173,000.004
Jul ’24₩235,500.00
₩291,800.00
+23.9%
34.5%₩410,000.00₩139,000.00₩150,100.005
Jun ’24₩261,000.00
₩263,800.00
+1.1%
33.6%₩410,000.00₩139,000.00₩130,600.005
May ’24₩236,000.00
₩234,126.98
-0.8%
30.8%₩290,000.00₩132,380.95₩135,000.003
Apr ’24₩221,500.00
₩194,126.98
-12.4%
32.3%₩280,000.00₩132,380.95₩147,000.003
Mar ’24₩218,500.00
₩177,428.57
-18.8%
32.6%₩280,000.00₩114,285.71₩158,000.005
Feb ’24₩137,100.00
₩138,428.57
+1.0%
20.1%₩190,476.19₩114,285.71₩190,400.005
Jan ’24₩128,000.00
₩134,724.13
+5.3%
20.3%₩190,476.19₩109,523.81₩241,000.006
Dec ’23₩113,047.62
₩135,714.29
+20.1%
19.8%₩190,476.19₩109,523.81₩222,500.006

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 00:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medy-Tox Inc. is covered by 28 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyeryeong KimCGS International
Hyonseok KimCLSA
null nullCredit Suisse